Zobrazeno 1 - 10
of 185
pro vyhledávání: '"McElhone, K."'
Autor:
Soomro, M, Stadler, M, Dand, N, Bluett, J, Jadon, D, Jalali‐najafabadi, F, Duckworth, M, Ho, P, Marzo‐Ortega, H, Helliwell, PS, Ryan, AW, Kane, D, Korendowych, E, Simpson, MA, Packham, J, McManus, R, Gabay, C, Lamacchia, C, Nissen, MJ, Brown, MA, Verstappen, SMM, Van Staa, T, Barker, JN, Smith, CH, Chalmers, R, Flohr, C, Watson, K, Prieto‐Merino, D, Alabas, O, Barker, J, Becher, G, Bewley, A, Burden, D, Morrison, S, Laws, P, Evans, I, Griffiths, C, Ahmed, S, Kirby, B, Kleyn, E, Lawson, L, Mackenzie, T, McPherson, T, McElhone, K, Murphy, R, Ormerod, A, Owen, C, Reynolds, N, Rashid, A, Smith, C, Warren, R, Siebert, S, Brown, S, McAteer, H, Schofield, J, FitzGerald, O, McHugh, N, Warren, RB, Bowes, J, Barton, A
Objectives Psoriatic arthritis (PsA) has a strong genetic component, and the identification of genetic risk factors could help identify the ~30% of psoriasis patients at high risk of developing PsA. Our objectives were to identify genetic risk factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::f08440eaf5186fd6994b5803172b23bb
Autor:
Yiu, ZZN, Mason, KJ, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD, Study Group, BADBIR
Publikováno v:
The British Journal of Dermatology
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Yiu, Z Z N, Mason, K J, Barker, J N W N, Hampton, P J, McElhone, K, Smith, C H, Warren, R B, Griffiths, C E M, Lunt, M & Burden, A D 2019, ' A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17849
Summary Background Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real‐world psoriasis population. Objectives Firstly, to investigate whether patient characteristics
Autor:
Rungapiromnan, W., Mason, K.J., Lunt, M., McElhone, K., Burden, A. D., Rutter, M.K., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M., Barker, Jonathan, Benham, Marilyn, Browne, Fiona, Evans, Ian, Hussain, Sagair, Kirby, Brian, Lawson, Linda, McPherson, Tess, Murphy, Ruth, Owen, Caroline, Ormerod, Anthony, Pearson, Eleanor, Reynolds, Nick, Richards, Josh, Smith, Catherine, BADBIR Study Group, .
Background:\ud The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.\ud \ud Objectives:\ud To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::247061b007c0ac992aff61dcccf8ae2f
https://eprints.gla.ac.uk/213580/1/213580.pdf
https://eprints.gla.ac.uk/213580/1/213580.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pan, S., Tsakok, T., Dand, N., Lonsdale, D.O., Loeff, F.C., Bloem, K., de Vries, A., Baudry, D., Duckworth, M., Mahil, S., Pushpa-Rajah, A., Russell, A., Alsharqi, A., Becher, G., Murphy, R., Wahie, S., Wright, A., Griffiths, C.E.M., Reynolds, N.J., Barker, J., Warren, R.B., David Burden, A., Rispens, T., Standing, J.F., Smith, C.H., Benham, M., Evans, I., Hussain, S., Kirby, B., Lawson, L., Mason, K., McElhone, K., Ormerod, A., Owen, C., Barnes, M.R., Di Meglio, P., Emsley, R., Evans, A., Payne, K.
Publikováno v:
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 13(2), 400-409. Wiley-Blackwell
Clinical and Translational Science, Vol 13, Iss 2, Pp 400-409 (2020)
Clinical and Translational Science
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T & Standing, J F & Smith, C H 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis : A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725, https://doi.org/10.1111/cts.12725
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T, Standing, J F, Smith, C H, Benham, M, Evans, I, Hussain, S, Kirby, B, Lawson, L, Mason, K, McElhone, K, Ormerod, A, Owen, C, Barnes, M R, Di Meglio, P, Emsley, R, Evans, A & Payne, K 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725
Clinical and Translational Science, Vol 13, Iss 2, Pp 400-409 (2020)
Clinical and Translational Science
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T & Standing, J F & Smith, C H 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis : A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725, https://doi.org/10.1111/cts.12725
Pan, S, Tsakok, T, Dand, N, Lonsdale, D O, Loeff, F C, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, C E M, Reynolds, N J, Barker, J, Warren, R B, David Burden, A, Rispens, T, Standing, J F, Smith, C H, Benham, M, Evans, I, Hussain, S, Kirby, B, Lawson, L, Mason, K, McElhone, K, Ormerod, A, Owen, C, Barnes, M R, Di Meglio, P, Emsley, R, Evans, A & Payne, K 2020, ' Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study ', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409 . https://doi.org/10.1111/cts.12725
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bcea23ca63518fef3372a4c62f0df85
https://pure.amc.nl/en/publications/using-realworld-data-to-guide-ustekinumab-dosing-strategies-for-psoriasis(356fdda6-87b8-4fbc-8cc1-218c18c81fd8).html
https://pure.amc.nl/en/publications/using-realworld-data-to-guide-ustekinumab-dosing-strategies-for-psoriasis(356fdda6-87b8-4fbc-8cc1-218c18c81fd8).html
Autor:
Rungapiromnan, W, Mason, KJ, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM, Grp, BADBIRS
Background\ud The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.\ud \ud Objectives\ud To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::749b488351b8d274b4c281508ed51993
https://eprints.keele.ac.uk/8508/1/jdv.16018.pdf
https://eprints.keele.ac.uk/8508/1/jdv.16018.pdf
Autor:
Yiu, Z.Z.N., Ashcroft, D.M., Evans, I., McElhone, K., Lunt, M., Smith, C.H., Walton, S., Murphy, R., Reynolds, N.J., Ormerod, A.D., Griffiths, C.E.M., Warren, R.B.
Publikováno v:
Yiu, Z Z N, Ashcroft, D M, Evans, I, McElhone, K, Lunt, M, Smith, C H, Walton, S, Murphy, R, Reynolds, N J, Ormerod, A D, Griffiths, C E M & Warren, R B 2019, ' Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register ( BADBIR ) ', British Journal of Dermatology . https://doi.org/10.1111/bjd.17036
The British Journal of Dermatology
The British Journal of Dermatology
Summary Background Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. Objectives To compare the risk of serious infections associated with infliximab in patients with chronic plaq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::44915d9e63a5b8b4248233c1908d425b
https://doi.org/10.1111/bjd.17036
https://doi.org/10.1111/bjd.17036
Autor:
Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB, Study Group, BADBIR
BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8cf6a3a4c015a21fa372ed481c660cf1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.